Streptococcus pneumoniae is a Gram-positive bacterium that can express more than 90 different capsule types (serotypes) and is often carried as a commensal in the human nasopharynx (NPX), but can also cause serious diseases by invading deeper tissues. Epidemiologic studies show that the prevalence of carriage and the efficiency of invasion are highly variable (>100-fold) among different pneumococcal serotypes. With the use of pneumococcal conjugate vaccines, the most commonly carried serotypes have changed (called 'serotype shift'), with serotype 11A having become one. However, serotype 11A has a very low invasiveness, and the molecular basis for 11A's low invasiveness and high rate of carriage is not known. By inactivating serotype 11A's wcjE and thus causing it to lose an acetyl group from its polysaccharide, we discovered that 11A often becomes 11E during the invasive pneumococcal infection of individual patients. We also found that 11A is more resistant to lysozyme than 11E is and that L-ficolin binds to 11A but not to 11E. L-ficolin is a recently discovered innate opsonin in the blood that resembles mannose binding lectin (MBL) in structure, targets acetyl groups, and initiates the lectin-dependent complement cascade by activating MBL- associated serine protease-2 (MASP-2). Based on these observations, we propose the overarching hypothesis that serotype 11A retains WcjE to resist lysozyme and thus survive in the NPX and that it loses WcjE function to become 11E and thus avoid L-ficolin and survive in the blood. To investigate this hypothesis, we will determine 1) whether L-ficolin is protective against serotype 11A but not against 11E isolates by testing L-ficolin's ability to opsonize serotype 11A but not 11E for phagocytosis, by measuring the serum levels of L-ficolin and MASP-2 in individuals with serotype 11A pneumococcal sepsis, and by testing another common wcjE+ serotype with L-ficolin reactivity for an undiscovered wcjE- subtype without L-ficolin reactivity; 2) whether the WcjE of serotype 11A makes pneumococci resistant to the murami- dase activity of lysozyme by comparing serotypes 11A and 11E isolates for their in vitro resistance to normal and mutant lysozymes and for their nasopharyngeal carriage in mice with or without lysozyme; and 3) whether WcjE enhances lysozyme resistance by helping Adr (attenuator of drug resistance) modify peptidoglycan. Our work is broadly relevant because wcjE is found in many different pneumococcal serotypes and because very little is known about L-ficolin's role in bacterial infections. Our work is also directly relevant to pneumococcal vaccin development because 11A has become one of the most common nasopharyngeal serotypes and because other newly emerging serotypes might be like 11A: they may interact with innate opsonins and thus be less of a health threat even if they become more common. Our work would also expand the concept of 'serotype' to include serotype specific interactions with innate opsonins, as well as antibodies, and this new concept may bring further innovations in vaccine designs against many pathogens.

Public Health Relevance

Pneumococci produce many different types of sugar coatings and it is known that some sugar coatings are better for their living in the nose but some are better in invading deeper parts of human body. My laboratory has discovered recently that some pneumococci may change their capsules as they move from the nose to the blood to avoid our immune defenses in the blood. We propose to study what makes the changes in the pneumococcal capsules since the knowledge will help us improve pneumococcal vaccines.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
High Priority, Short Term Project Award (R56)
Project #
Application #
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Taylor, Christopher E,
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Alabama Birmingham
Schools of Medicine
United States
Zip Code
Geno, K Aaron; Spencer, Brady L; Nahm, Moon H (2015) Rapid and efficient purification of ficolin-2 using a disposable CELLine bioreactor. J Immunol Methods 424:106-10
Geno, K Aaron; Gilbert, Gwendolyn L; Song, Joon Young et al. (2015) Pneumococcal Capsules and Their Types: Past, Present, and Future. Clin Microbiol Rev 28:871-99
Park, In Ho; Geno, K Aaron; Yu, Jigui et al. (2015) Genetic, biochemical, and serological characterization of a new pneumococcal serotype, 6H, and generation of a pneumococcal strain producing three different capsular repeat units. Clin Vaccine Immunol 22:313-8
Brady, Allison M; Calix, Juan J; Yu, Jigui et al. (2014) Low invasiveness of pneumococcal serotype 11A is linked to ficolin-2 recognition of O-acetylated capsule epitopes and lectin complement pathway activation. J Infect Dis 210:1155-65
Calix, Juan J; Brady, Allison M; Du, Victor Y et al. (2014) Spectrum of pneumococcal serotype 11A variants results from incomplete loss of capsule O-acetylation. J Clin Microbiol 52:758-65
Brady, Allison M; Geno, K Aaron; Dalecki, Alex G et al. (2014) Commercially available complement component-depleted sera are unexpectedly codepleted of ficolin-2. Clin Vaccine Immunol 21:1323-9
Park, In Ho; Geno, K Aaron; Sherwood, Logan K et al. (2014) Population-based analysis of invasive nontypeable pneumococci reveals that most have defective capsule synthesis genes. PLoS One 9:e97825
Brady, Allison M; Spencer, Brady L; Falsey, Ann R et al. (2014) Blood collection tubes influence serum ficolin-1 and ficolin-2 levels. Clin Vaccine Immunol 21:51-5
Keller, L E; Jones, C V; Thornton, J A et al. (2013) PspK of Streptococcus pneumoniae increases adherence to epithelial cells and enhances nasopharyngeal colonization. Infect Immun 81:173-81
Song, Joon Young; Moseley, M Allen; Burton, Robert L et al. (2013) Pneumococcal vaccine and opsonic pneumococcal antibody. J Infect Chemother 19:412-25

Showing the most recent 10 out of 20 publications